mRNA decapping is a common step shared between two important mRNA decay pathways in yeast, Saccharomyces cerevisiae. To investigate how mRNAs are decapped, we have developed an assay that can be easily used to measure the decapping activity. This assay has been used to isolate yeast strains with altered decapping activities. The results demonstrated that decreased decapping activity in vitro corresponds well with the decapping-deficient phenotype in vivo. This assay has been applied to the purified yeast decapping enzyme Dcp1 protein as well as crude yeast extracts and Xenopus oocyte extracts. © 1999 Academic Press Key Words: mRNA decay; mRNA turnover; decapping activity; Xenopus oocyte.
The mRNA abundance in vivo is determined mainly by the rate of its synthesis and the rate of its decay. In eukaryotic cells, the decay rates of mRNAs can differ from each other by more than 50-fold. Some mRNAs turn over with half-lives that are on the order of minutes, while others are stable for days or weeks [reviewed in Peltz et al. (20) , Ross (22) , Beelman and Parker (3), Jacobson and Peltz (13) , Caponigro and Parker (5) , and Wickens et al. (31) ]. In addition, the decay rates of certain mRNAs are modulated in response to many factors, such as different developmental stages, cell types, or environmental signals [reviewed in Peltz et al. (20) , Ross (22) , and Jacobson and Peltz (13) ]. These results indicate that mRNA stability is an important mechanism in regulating gene expression. A number of laboratories have focused on elucidating the cellular mechanisms that control mRNA decay rates [reviewed in Jacobson and Peltz (13) ]. These studies include the characterization of both the cis-acting elements and the trans-acting factors that are involved in this process.
Decapping is an important rate-determining step in decay. Two major mRNA degradation pathways that have been intensively investigated are the poly(A)-shortening-dependent and nonsense-mediated mRNA decay (NMD) pathways [poly(A) shorteningindependent; reviewed in Beelman and Parker (3), Chen and Shyu (6) , Caponigro and Parker (5) , and Jacobson and Peltz (13) ]. The poly(A)-shorteningdependent decay pathway has been demonstrated to degrade a large number of wild-type transcripts in both yeast and mammalian cells (7, 17, 26, 27) [reviewed in Chen and Shyu (6), Caponigro and Parker (5), and Jacobson and Peltz (13) ]. In this pathway, following shortening of the poly(A) tail the 5Ј cap structure is removed by a decapping enzyme [see Shyu et al. (26, 27) , Decker and Parker (7), Beelman et al. (2) , Muhlrad and Parker (18) , and Muhlrad et al. (16) ; reviewed in Ross (22) , Caponigro and Parker (5) , and Jacobson and Peltz (13) ]. The rate-limiting steps are both the decapping process and deadenylation. cis-Acting elements, which are able to promote poly(A) shortening, destabilize mRNAs. Mutations that cripple or inactivate these elements result in stabilization of these transcripts (17, 27) . On the other hand, the NMD pathway in both yeast and mammalian cells degrades nonsense-containing transcripts prior to shortening of the poly(A) tail (10, 18) . Removal of the 5Ј cap also occurs as the ratelimiting event in the NMD pathway (10, 16) . For both decay pathways, the uncapped transcripts are then degraded by the 5Ј 3 3Ј Xrn1p exoribonuclease in yeast, Saccharomyces cerevisiae (10, 12, 18) .
Enzymes or activities that decap mRNAs. The 5Ј-terminal cap structure, m 7 G(5Ј)ppp(5Ј)N, is a common feature of almost all eukaryotic mRNAs [reviewed in Shatkin (23) and Banerjee (1)]. Therefore, the cap structure has been proposed to participate in RNA splicing, translation, transport from the nucleus to the cytosol, and degradation. Hydrolysis of the cap structure is essential for complete turnover of the mRNA chains (23) . The fact that decapping is an important event in the decay of both wild-type and nonsense-containing transcripts indicates that the enzymes and factors that carry out and regulate this activity are important in controlling mRNA turnover rates. However, since an easily defined and selectable phenotype was lacking, it was only recently that a decapping enzyme was purified from yeast and its gene identified (2) . The decapping activity copurified with a protein of approximately 31 kDa molecular weight (2, 30) . Microsequencing of this protein led to the identification of the DCP1 gene. Cells harboring a dcp1 disruption were viable with a twofold increase in doubling time and promoted stabilization of both wild-type and nonsensecontaining mRNAs (2, 11) . Further analysis demonstrated that the poly(A) tails of these transcripts deadenylated normally but their decapping rates were greatly reduced. Analysis of Dcp1p demonstrated the following: (1) (15, 29) . Several nonspecific nucleotide pyrophosphatases, which also demonstrate decapping activity, have been partially purified from other systems, such as potato, tobacco, and HeLa cells (14, 19, 24) . The characteristics of these pyrophosphatases are listed below (see Table 1 for decapping cleavage sites of these pyrophosphatases). However, thus far no genes encoding these enzymes have been cloned. Since they do not have specificity for mRNA, it is still not clear whether these pyrophosphatases are truly the decapping enzyme in these species.
One earlier decapping assay was previously described (28) . In the assay, substrate [ H counter. A simpler assay that could monitor the decapping activity of a large number of samples and cell extracts was developed. This decapping assay is easily quantified and showed that in yeast a decreased decapping activity in vitro corresponded well with the decapping-deficient phenotype in vivo (2) . Furthermore, this method has been applied to Xenopus oocyte extracts, in which both nonspecific pyrophosphatase activity and specific decapping activity have been observed. This method and its application to yeast and oocyte extracts are described below.
METHODS

Preparation of the Cap-Labeled RNA Substrates
The cap-labeled RNA substrates (5Ј-[
GpppN-RNA) were prepared by capping RNAs containing (25) The reaction was incubated at 37°C for 2 h. Cap-labeled RNAs were then separated from free [␣-32 P]GTP nucleotide by chromatography through a Sepharose CL-6B column. The CL-6B beads were washed and equilibrated with 1ϫ TE (pH 7.5) before use. A column was prepared by filling a 1-ml pipet tip with CL-6B beads. The column was spun at 630 rpm in a Beckman GS-6 centrifuge for 5 min. The cap-labeled substrate was eluted by adding 50 l 1ϫ TE (pH 7.5) and spinning the column at 630 rpm for 5 min each time. A total of seven elutions were collected and stored at Ϫ70°C. The quality of the purified [␣-
32 P] 7m GpppN-RNA was confirmed by gel electrophoresis as well as by thin-layer chromatography (TLC analysis; see Fig. 1, lane 1) .
Measuring the Decapping Activity of Purified Dcp1 Protein
To test the validity of this assay, the decapping activity of purified Dcp1p was examined. The DCP1 open reading frame (ORF) was fused with a Flag sequence at its N terminus and the decapping enzyme was purified from yeast by an anti-Flag antibody affinity column (32) . Varying amounts of Dcp1p were incubated with cap-labeled RNA substrate and the enzyme activity was determined as follows (Fig. 1) . The reactions were incubated at 37°C for 30 -40 min and were terminated by addition of 2 l of 0.5 M EDTA (pH 8.0).
The products of the decapping reaction were ana-
FIG. 1.
Decapping assay with purified Dcp1p. The in vitro transcribed mRNA was synthesized by T7 RNA polymerase and capped by vaccinia capping enzyme in the presence of [␣-32 P]GTP and SAM. The cap-labeled substrate was then purified on a Sepharose CL-6B column. Dcp1p and Upf1p were purified on an anti-flag affinity column (32) . Eighty nanograms of purified Dcp1 protein was incubated with cap-labeled substrate for various lengths of time as indicated (lanes 2-10). As control, 150 ng purified Upf1p was also incubated with substrate for 50 min (lane 11). The decapping activity for 80ng Dcp1p was examined in the presence of 20 mM EDTA (lane 12), as well as boiled Dcp1p (lane 13). The decapping products were separated on thin-layer chromatography plates and detected by autoradiography.
lyzed by applying the reaction mixtures to Bakerflex cellulose PEI-F TLC plates (VWR, JT4474-4 GMP, m 7 GDP, GMP, and GDP markers (Sigma) on the TLC plate as controls (see Figs. 1, 2, and 3 for examples) . The markers were visible on cellulose PEI-F TLC plates under UV light at a wavelength of 254 nm. The relative mobility of m 7 GMP is greatest, followed by m 7 GDP, GMP, and GDP respectively (Fig. 2) .
As expected, m 7 GDP was observed as a reaction product (Fig. 1, see lanes 2-10) . In addition, unmethylated GDP was also identified as a product in the decapping reaction under the conditions outlined above (Fig. 2) . Using a nuclease P1-treated substrate and TLC assay, we found that a subset of our capped-labeled RNA substrate harbored an unmethylated 5Ј cap (data not shown) since the capping reaction is not very efficient. This result was not surprising, since the yeast decapping enzyme does not distinguish the methylated and unmethylated 5Ј cap structures of mRNAs (29) .
Several controls were performed to validate the decapping assay described above. Characterization of the decapping enzyme demonstrated a requirement for divalent cations such as Mg 2ϩ for its full activity. Consistent with this observation, 20 mM EDTA inactivates the decapping enzyme (Fig. 1,  lane 12 ) and the enzyme also lost its activity after being boiled (Fig. 1, lane 13) (29) . Taken together, these results demonstrate that we have developed an accurate and easily used assay to monitor decapping activity in vitro.
Measuring Decapping Activity in Yeast Cell Extracts
Preparation of Yeast Cell Extracts
Extracts were prepared by harvesting 10 ml of cells grown to an OD 600 of 0.7-1.0 and washing the cells with 1 ml of cold buffer XO (10 mM Tris, pH 7.6, 100 mM potassium acetate, 2 mM magnesium acetate, 2 mM DTT). The cells were resuspended in an equal volume of cold buffer XOR (buffer XO containing 2 g/ml each leupeptin, pepstatin A, aprotinin) and an equivalent volume of acid-washed glass beads was added to the cells. The mixture was vortexed for 15 s and cooled on ice for 45 s. The vortexing procedure was repeated a total of six times. The extract was centrifuged at 13,000 rpm for 10 min at 4°C in a microcentrifuge, the supernatant was transferred to a fresh tube, and the protein concentration of the extract was determined by the Bio-Rad Protein Assay (Catalog 5000006).
Monitoring the Decapping Activity in Yeast Cell Extracts
To determine decapping activity in yeast extracts, 20 -50 g of yeast cell extract was used in the decapping assay instead of purified Dcp1p as described above. The mixtures were usually incubated at 30 or 37°C for 40 min, unless otherwise indicated. Besides 7m GDP and GDP, 7m GMP and GMP were also observed when yeast cell extracts were used. The GMP results from rapid hydrolysis of GDP, the cleavage product from the capped, but unmethylated substrate (data not shown). Since yeast cell extracts also hydrolyze 7m GDP but at a very slow rate, 7m GMP could have resulted from hydrolysis of 7m GDP. It is also possible that a portion of GMP and 7m GMP was produced by some unknown pyrophosphatase in the extracts. It has been shown that the gag protein of L-A dsRNA virus was able to cleave the cap structure from mRNAs to produce 7m GMP (4). Consistent with the purified decapping enzyme, the decapping activity in extracts is also sensitive to 10 mM EDTA as well as (Fig. 2, lanes 5 and 6) boiling of the sample (Fig. 2, lane 8) . The decapping activity was equivalent in wild-type and xrn1 Ϫ strains (Fig. 2) , which is expected since the Xrn1p degrades already uncapped transcripts. The assay is linear for decapping activity for 40 min, indicating that we can accurately monitor altered decapping activity in extracts. In addition, dcp1⌬ strains demonstrated a fivefold reduction in decapping activity compared with wild-type strains when our assay was used to monitor decapping in these extracts (2) . These results demonstrate that we have developed an accurate assay to monitor decapping activity in yeast cell extracts and that the decapping activity in vitro corresponds to the decapping deficiency in vivo.
Measuring Decapping Activity in Xenopus Oocyte Extracts
Preparation of Xenopus Oocytes and Embryo
Extracts Each extract was prepared by homogenizing 50 oocytes or embryos at the indicated stage in 10 l of either XOR buffer or J buffer (10 mM Hepes-KOH, pH 7.2, 70 mM KCl, 1 mM MgCl 2 , 2 mM DTT, 0.1 mM EDTA, 10% v/v glycerol, 0.1 mM PMSF containing 1 g/ml of leupeptin, soybean trypsin inhibitor, and pepstatin A) by repeated pipetting with a P200 tip. Homogenates were clarified by spinning in a microfuge for 10 min at 4°C.
Monitoring Decapping Activity in Xenopus Extracts
Maternal mRNA expression in early development is regulated at the level of mRNA stability as well as translational efficiency. For the most part, Xenopus oocyte mRNAs are very stable; some may even have half-lives as long as 3 months (9) . By contrast, embryonic mRNAs are much more labile; most are degraded by the time new transcripts appear at the midblastula transition (stage 8). These observations imply that the degradation machinery is off or operates at low level in oocytes and early embryos but substantially increases in activity in later embryos (21) . Several studies have focused on the poly(A) tail as a major determinant in mRNA stability, since for injected RNAs, those that carry a poly(A) tail are generally more stable than those lacking the tail. However, some maternal mRNAs are deadenylated after fertilization but degraded around the midblastula transition 7 h later (8) .
We asked whether decreased decapping activity could also account for the stability of poly(A) Ϫ mRNAs. To test this hypothesis, we have examined the decapping activity in extracts prepared from the Xenopus oocytes at different developmental stages (Fig. 3) . The results indicated there were two pyrophosphatase activities in Xenopus oocyte extracts. One activity produces 7m GMP and does not change much during the development of the oocyte. Since it is sensitive to 7m GpppG and 7m GpppA but is resistant to 10 mM EDTA, this activity is similar to that of those nonspecific pyrophosphatase observed in tobacco, potato, and HeLa cells. In contrast, the second activity produces 7m GDP and is sensitive to EDTA but not cap analogs, just like the decapping enzyme in yeast. More interestingly, this activity varies during the development of oocyte. The extract prepared from early stages of embryo shows the lowest activity and the activity starts to increase dramatically after stage 8 embryo which is consis -FIG. 3 . Decapping activity in Xenopus oocyte extracts. OX, EX, 8X, 20X, and 34X refer to the extracts prepared in XOR buffer and correspond to stage VI oocytes, unfertilized eggs, stage 8 (midblastula), stage 20 (late neurula), and stage 34 (tadpole), respectively. OJ, EJ, 8J, 20J, and 34J are extracts from the same stages indicated above but were prepared in J buffer. The same amount of protein from each extract was determined for decapping activity. Furthermore, the effects of 7m GpppA, 7m GpppG, and EDTA on decapping activity were examined. tent with poly(A) Ϫ mRNA stability during the development of Xenopus oocyte. These results are significant since it supports our hypothesis that the real decapping activity is low when poly(A) Ϫ mRNAs accumulate at the early stages of oocyte development and it also suggests that there is a Dcp1p homolog in higher eukaryotes, indicating that the mRNA turnover pathways in yeast might exist in other systems as well. More experiments are needed to establish a fine regulation of decapping activity during Xenopus oocyte development and eventually to isolate the decapping enzyme.
